Amarin Corp Plc (AMRN)

[Jasbg]

How to 'get wheels rolling' for Amarin ?

As I see it 'the Legal battle of USA market is lost'. Spending months - possible years - fighting in US courts (and at the same time ever WAITING) - is not the way to go.

Action is needed. Courage and determination is needed from JT and BOD.

The answer to 'losing patents in USA' is actually right in front of Amarin. I'v seen a couple of others mention it here also. There has already been contact to the worlds third biggest generic company - Teva.

It would be totally logic to 'go generic NOW - in full cooperation with Teva in US market. New strategy for marketing (Teva has the power) - sales force not needed anymore.
-------------------------------

Teva is strong in Europe also - seems logic to research every option regarding partnership (possible BO) with Teva - as a first for US market.

-------------------------------

About Teva:

3. Teva Pharmaceutical – $9.67bn

world’s biggest generic pharmaceutical companies Teva Pharma’s revenue decline due to price erosion and volume declines was offset by new generic drug launches in 2018. Image courtesy of Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals’ 2018 revenues in North America declined by 22%, compared to 2017, due to price erosion and volume reductions. The company launched generic versions of drugs such as Estrace®, Syprine®, Solodyn®, Aloxi®, Lialda®, Uceris®, and Elidel® in the the region in 2018.

The company’s European revenues increased by 4% to $3.6bn, compared to 2017. The revenue growth was a result of an increase in OTC drug sales and the launch of new products, which offset the impact of price reductions of generics in the first half of 2018. The revenue was, however, affected marginally in the second half of 2018 due to the dissolution of Teva’s joint venture with PGT Healthcare.

In the international generics segment, Teva reported a 15% decline in net sales in 2018 compared to 2017 due to a negative impact on sales in Japan and Russia due to regulatory pricing reductions. The company launched seven generic drugs in 2018, of which five were launched in the first quarter alone.

Teva Pharmaceutical is an Israel-based pharmaceutical company that offers diverse products in a wide range of segments such as speciality, generic, OTC, and APIs.

Jasbg